Anika Therapeutics, Inc. — Fiscal 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual Form 10-K rather than a standalone fourth-quarter filing, although it identifies a material impairment charge recorded in the fourth quarter.
Business context
Anika is a global joint-preservation company focused on osteoarthritis pain management, regenerative solutions, sports medicine, Arthrosurface joint solutions, and legacy non-orthopedic products. Its portfolio is built substantially around hyaluronic-acid technology. The company sells through commercial partners, hospitals and ambulatory surgical centers, distributors, and direct and independent sales channels.
- OA Pain Management includes Monovisc, Orthovisc, and Cingal outside the United States.
- Joint Preservation and Restoration includes Tactoset, Integrity, Hyalofast outside the United States, sports-medicine products, and Arthrosurface implants.
- Mitek accounted for 45% of 2023 revenue and 46% of accounts receivable at year-end.
- International customers represented 26% of product sales in 2023, compared with 24% in 2022.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $166.7 million | $156.2 million | Up 7% |
| Gross profit | $103.1 million | $93.6 million | Up 10% |
| Gross margin | 62% | 60% | Up 2 percentage points |
| Operating loss | $(87.6) million | $(19.4) million | Increased loss |
| Net loss | $(82.7) million | $(14.9) million | Increased loss |
| Loss per diluted share | $(5.64) | $(1.02) | Wider loss |
| Adjusted EBITDA | $15.5 million | $12.6 million | Up $2.9 million |
| Operating cash flow | $(1.8) million | $4.4 million | Declined $6.2 million |
| Cash and cash equivalents | $72.9 million | $86.3 million | Down $13.5 million |
Adjusted net loss improved to $4.3 million from $7.1 million, and adjusted diluted loss per share improved to $(0.30) from $(0.49). These are non-GAAP measures and exclude, among other items, the intangible-asset impairment, acquisition-related amortization, arbitration costs, software-project discontinuation costs, and shareholder-activism costs.
Revenue by product family
| Product family | 2023 revenue | 2022 revenue | Change |
|---|---|---|---|
| OA Pain Management | $101.9 million | $92.0 million | Up 11% |
| Joint Preservation and Restoration | $54.9 million | $50.4 million | Up 9% |
| Non-Orthopedic | $9.9 million | $13.9 million | Down 29% |
OA Pain Management growth reflected higher Monovisc sales, favorable ordering patterns, and continued double-digit international growth for Cingal. Joint Preservation and Restoration benefited from adoption of newer products, including X-Twist, and higher international sales. Non-Orthopedic revenue declined primarily because of lower veterinary orders and the loss of certain legacy distributor business after 2022 last-time purchases.
Material changes versus the prior comparable period
- Revenue increased 7%, while gross margin improved from 60% to 62% because of higher volumes, manufacturing efficiencies, and lower product-rationalization charges, partially offset by inflation in raw materials and freight.
- Research and development expense increased 16% to $32.7 million, driven by global regulatory compliance, including EU MDR, and development of the Integrity product.
- SG&A increased 13% to $95.8 million. It included approximately $13.0 million of non-recurring costs related to the Parcus Medical unitholder arbitration settlement, shareholder activism, software-project discontinuation, and other corporate costs.
- Anika recorded a $62.2 million non-cash impairment charge in the fourth quarter on intangible assets associated with the Parcus Medical and Arthrosurface asset groups. The impairment reflected lower expected revenue growth and related cash flows.
- Inventories increased to $64.6 million gross, including $46.4 million classified as current inventory, from $56.5 million gross at the prior year-end. Inventory growth was associated partly with new product launches, while reserves increased to approximately $11.7 million from $9.9 million.
- Cash flow from operations turned negative, principally because of non-recurring cash costs and a $11.4 million increase in inventories.
- The company repurchased $5.0 million of common stock through an accelerated share repurchase program, receiving 188,029 shares in 2023.
Debt, liquidity, and capital resources
- Anika had $72.9 million of cash and cash equivalents at December 31, 2023 and no investments.
- The company had no outstanding borrowings under its $75.0 million senior revolving credit facility and was in compliance with its covenants. Subject to lender approval and other conditions, total commitments could increase to $150.0 million.
- Lease liabilities totaled $26.9 million, with $37.0 million of undiscounted operating-lease payments due over future periods.
- Working capital was $132.2 million, compared with $141.6 million at December 31, 2022.
- Management stated that operating cash flows, cash on hand, and credit-facility availability are expected to be sufficient for anticipated operating needs and continued investment; the filing does not provide formal revenue or earnings guidance.
Outlook, management commentary, and unusual items
- Management plans continued investment in research and development, regulatory compliance, manufacturing scale-up, the U.S. commercial organization, ambulatory surgical center-focused products, and international expansion.
- Integrity received FDA clearance in August 2023, entered limited market release in November 2023, and had completed more than 100 cases by year-end. Full market release was targeted for mid-2024.
- The X-Twist Biocomposite system received FDA clearance in August 2023 and launched in early 2024; the PEEK version was broadly launched in early 2023.
- Hyalofast’s U.S. pivotal trial enrolled 200 patients. Management targeted a first modular PMA submission in 2024, completion of the two-year follow-up in early 2025, a final PMA module in 2025, and a potential U.S. launch by 2026.
- Cingal remains commercially unavailable in the United States. Following a 2023 FDA Type C meeting, Anika was awaiting FDA feedback on proposed non-clinical next steps and was evaluating whether and how to pursue another U.S. clinical trial and potential commercial partnerships.
- Management stated that the integration of the 2020 Parcus Medical and Arthrosurface acquisitions has taken longer and required more expense than expected. The 2023 impairment indicates lower near-term expectations for those businesses.
- The company stated that cybersecurity incidents had not materially affected the business as of the filing date, and management concluded that disclosure controls and internal control over financial reporting were effective. A prior material weakness related to a subsidiary credit-card program was reported as remediated in 2023.
Principal risks and contingencies
- Customer concentration and dependence on Mitek, including Mitek’s control over U.S. Monovisc and Orthovisc marketing, pricing, promotion, and reimbursement strategy.
- Competition, healthcare-provider consolidation, pricing pressure, reimbursement changes, and possible exclusion from group purchasing organizations or integrated delivery networks.
- Regulatory delays or failures involving Cingal, Hyalofast, Integrity, and other products; ongoing FDA, EU MDR, clinical-trial, and post-market compliance requirements.
- Supply-chain concentration, including reliance on limited suppliers and a single contract manufacturer for certain Arthrosurface products, with potential lead times of a year or more.
- Execution and integration risks associated with the Parcus Medical and Arthrosurface acquisitions, including the possibility of further impairment charges.
- Negative operating cash flow, inventory exposure, potential future capital needs, and possible dilution or restrictive terms if financing is required.
- Product liability, intellectual-property disputes, data privacy, cybersecurity, foreign-exchange, international operating, and healthcare fraud-and-abuse risks.
- Shareholder activism and related advisory and professional costs; Caligan Partners nominated two director candidates for the 2024 annual meeting after entering a 2023 cooperation agreement with Anika.
Facts investors should verify
- Whether the expected full-market release and adoption of Integrity and X-Twist Biocomposite occur on schedule and generate material revenue.
- FDA feedback and the regulatory path, cost, and timing for U.S. commercialization of Cingal and Hyalofast.
- Whether revenue growth in Parcus Medical and Arthrosurface products improves enough to avoid additional impairment or restructuring charges.
- Inventory aging, reserve adequacy, demand forecasts, and the effect of new product launches on working capital and operating cash flow.
- The durability of the Mitek relationship and the percentage of revenue and receivables concentrated with Mitek.
- Cash-burn trends, covenant compliance, credit-facility availability, and whether additional capital becomes necessary.
- Progress in acquisition integration, remediation of internal controls, and the outcome of shareholder activism at the 2024 annual meeting.